Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19179235 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | April 2025 | December 2025 | Allow | 8 | 1 | 1 | No | No |
| 19039174 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | January 2025 | September 2025 | Abandon | 8 | 1 | 0 | No | No |
| 18912218 | MIRDAMETINIB TREATMENT | October 2024 | July 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18912367 | MIRDAMETINIB TREATMENT | October 2024 | January 2026 | Abandon | 15 | 2 | 0 | No | No |
| 18904487 | ROCAGLATE DERIVATIVES AND USES THEREOF | October 2024 | February 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 18903487 | 2-AMINOMETHYLIMIDAZOLE MIMICS OF NS4A AND THEIR EFFECT THEREOF ON HEPATITIS C VIRUS NS3 PROTEASE | October 2024 | June 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18847298 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | September 2024 | September 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18800581 | NK3 MODULATORS AND USES THEREOF | August 2024 | November 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18764274 | LASOFOXIFENE TREATMENT OF BREAST CANCER | July 2024 | May 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18636905 | 3-(3-(1,3-DIOXOISOINDOLIN-2-YL) PROPYL)-5-(4-FLUOROBENZYLIDENE) THIAZOLIDINE-2,4-DIONE AS A POTENTIAL ANTITUMOR AND APOPTOTIC INDUCER | April 2024 | July 2024 | Allow | 3 | 0 | 0 | No | No |
| 18681394 | COLCHICINE SOLUTION | February 2024 | September 2024 | Allow | 7 | 1 | 0 | No | No |
| 18525536 | METHYLQUINAZOLINONE DERIVATIVES | November 2023 | August 2025 | Abandon | 21 | 3 | 0 | Yes | Yes |
| 18565245 | TRIAZINYLMETHYLCYCLOALKYLCARBOXYLIC ACID DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | November 2023 | February 2026 | Allow | 27 | 0 | 0 | Yes | No |
| 18560806 | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME | November 2023 | June 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18557255 | METHOD FOR PRODUCING PYRROLIDINE COMPOUND | October 2023 | February 2026 | Allow | 28 | 0 | 0 | Yes | No |
| 18373404 | CYCLIC AZASTANNANE AND CYCLIC OXOSTANNANE COMPOUNDS AND METHODS FOR PREPARATION THEREOF | September 2023 | March 2024 | Allow | 6 | 1 | 0 | No | No |
| 18547100 | PSILOCYBIN ANALOGS, SALTS, COMPOSITIONS, AND METHODS OF USE | August 2023 | December 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18361352 | INHIBITORS OF RNA-GUIDED NUCLEASES AND USES THEREOF | July 2023 | March 2026 | Allow | 31 | 0 | 1 | Yes | No |
| 18272709 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | July 2023 | November 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18222662 | TETRACYCLIC COMPOUNDS AS DGK INHIBITORS | July 2023 | November 2025 | Allow | 28 | 0 | 0 | No | No |
| 18305332 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | April 2023 | April 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18300315 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | April 2023 | August 2024 | Allow | 16 | 1 | 1 | No | No |
| 18247281 | CRYSTAL FORM OF MULTI-SUBSTITUTED BENZENE RING COMPOUND MALEATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | March 2023 | October 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18026684 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | March 2023 | September 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18026608 | CASEIN KINASE 1 DELTA MODULATORS | March 2023 | September 2025 | Allow | 30 | 0 | 0 | No | No |
| 18025390 | SALT OF COMPOUND FOR DEGRADING BTK, CRYSTAL FORM THEREOF, AND USE THEREOF IN MEDICINE | March 2023 | March 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18021032 | SALT FORM AND CRYSTAL FORM OF JAK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | February 2023 | January 2026 | Allow | 35 | 1 | 0 | No | No |
| 18020486 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | February 2023 | January 2026 | Allow | 36 | 1 | 1 | No | No |
| 18166020 | BENZIMIDAZOLE DERIVATIVES COMPOSITIONS | February 2023 | October 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17792472 | COMPOSITIONS OF SUBSTITUTED PYRAZOLOPYRIMIDINES AND USES THEREOF | February 2023 | February 2026 | Allow | 43 | 0 | 1 | No | No |
| 18040935 | Compositions and Methods for the Treatment and Diagnosis of Cancer | February 2023 | August 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18040884 | MASITINIB FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER | February 2023 | November 2025 | Allow | 33 | 0 | 0 | No | No |
| 18017104 | SALT AND CRYSTAL FORM OF PYRIMIDINE COMPOUND, AND PREPARATION METHODS THEREFOR | January 2023 | January 2026 | Allow | 36 | 1 | 0 | No | No |
| 18155431 | IRON CATALYZED HIGHLY ENANTIOSELECTIVE CIS-DIHYDROXYLATION OF QUINONES | January 2023 | December 2024 | Allow | 23 | 2 | 1 | No | No |
| 18002941 | LONG-ACTING LOW-ADDICTION HNK DERIVATIVE AND PREPARATION METHOD THEREFOR | December 2022 | July 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18083222 | CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | December 2022 | March 2026 | Allow | 39 | 1 | 0 | Yes | No |
| 18064173 | BICYCLIC AMINES AS CDK12 INHIBITORS | December 2022 | February 2024 | Allow | 14 | 0 | 1 | No | No |
| 18000205 | INDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | November 2022 | January 2026 | Allow | 38 | 1 | 1 | No | No |
| 17927919 | Methods of Treatment Using ICAM-Modulating Agents | November 2022 | January 2026 | Allow | 38 | 1 | 1 | Yes | No |
| 18000049 | INHIBITORS OF TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) AND USES THEREOF | November 2022 | December 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17927571 | NEW THERAPY FOR THE TREATMENT OF TUMORS | November 2022 | December 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17999505 | 1-((1H-PYRAZOL-4-YL)METHYL)-3-(PHENYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS GPR139 ANTAGONISTS FOR THE TREATMENT OF E.G. DEPRESSION | November 2022 | January 2026 | Allow | 38 | 1 | 1 | Yes | No |
| 17988340 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | November 2022 | December 2024 | Allow | 25 | 2 | 1 | No | No |
| 17998333 | CRYSTALLINE FORMS AND FORMULATIONS OF A VCP/p97 INHIBITOR | November 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 17998048 | AMINO ACID DERIVATIVE CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG STRUCTURE AND PREPARATION METHOD AND APPLICATION THEREOF | November 2022 | October 2025 | Allow | 35 | 0 | 1 | Yes | No |
| 17974680 | Isomer-Specific Neuroprotective Effect of Natural Resveratrol | October 2022 | August 2025 | Abandon | 33 | 3 | 0 | No | No |
| 17972963 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS USING VOLASERTIB | October 2022 | February 2026 | Allow | 40 | 5 | 0 | Yes | No |
| 18046648 | CANCER TREATMENT USING FGFR INHIBITORS AND PLK1 INHIBITORS | October 2022 | December 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17917027 | COMBINATION THERAPIES FOR INHIBITION OF POLO-LIKE KINASE 4 | October 2022 | August 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17916439 | CXCR5 Antagonists and Methods of Treating Diseases or Disorders Using Same | September 2022 | May 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 17914659 | HSP70 Inhibitors and Methods of Using Same | September 2022 | January 2026 | Allow | 40 | 1 | 1 | No | No |
| 17940576 | METHOD FOR PREPARING PHTHALONITRILE-BASED COMPOUND | September 2022 | July 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17899672 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | August 2022 | May 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17907943 | Substituted N-Benzhydrylacetamide Inhibitors of Jumanji Domain Histone Demethylases for the Treatment of Cancer | August 2022 | November 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17641265 | MALEATE OF NICOTINYL ALCOHOL ETHER DERIVATIVE, CRYSTAL FORM THEREOF, AND APPLICATION THEREOF | August 2022 | July 2025 | Allow | 40 | 0 | 0 | Yes | No |
| 17788154 | PROTEIN DEGRADATION AGENT COMPOUND PREPARATION METHOD AND APPLICATION | June 2022 | January 2025 | Allow | 31 | 0 | 0 | No | No |
| 17786399 | RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION | June 2022 | July 2025 | Allow | 37 | 0 | 1 | Yes | No |
| 17841079 | FORMULATIONS OF TIE-2 ACTIVATORS AND METHODS OF USE THEREOF | June 2022 | November 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17784179 | Salts of R-ketorolac | June 2022 | July 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17835245 | METHYLQUINAZOLINONE DERIVATIVES | June 2022 | August 2024 | Allow | 26 | 1 | 0 | Yes | No |
| 17772888 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | April 2022 | May 2025 | Allow | 37 | 0 | 0 | Yes | No |
| 17729691 | COMPOSITION FOR RELIEVING HANGOVER AND IMPROVING LIVER FUNCTION | April 2022 | September 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17716963 | CRYSTALLINE FORMS OF N-(4-(1-(2,6-DIFLUOROBENZYL)-5-((DIMETHYLAMINO)METHYL)-3-(6-METHOXY-3-PYRIDAZINYL)-2,4-DIOXO-1,2,3,4-TETRAHYDROTHIENO[2,3-D]PYRIMIDIN-6-YL)PHENYL)-N'-METHOXYUREA | April 2022 | February 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17761097 | COMBINATION OF SMALL MOLECULE INHIBITOR OF THE PD-1/PD-L1 INTERACTION AND ANTI-PD-1 ANTIBODY FOR TREATING CANCER | March 2022 | January 2026 | Abandon | 46 | 1 | 0 | No | No |
| 17639757 | VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USE | March 2022 | January 2026 | Abandon | 46 | 1 | 1 | No | No |
| 17637439 | NOVEL LOBARIC ACID DERIVATIVE HAVING PTP-1B INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | February 2022 | February 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17650561 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | February 2022 | January 2026 | Allow | 48 | 1 | 1 | Yes | No |
| 17669122 | SEQUESTRATION COMPOUNDS FOR TREATMENT OF SUBSTANCE USE DISORDER AND USES THEREOF | February 2022 | November 2025 | Allow | 45 | 1 | 0 | No | No |
| 17629457 | AGENT FOR TREATING, PREVENTING, OR IMPROVING PSYCHIATRIC AND NERVOUS SYSTEM DISORDERS OR SYMPTOMS | January 2022 | October 2025 | Allow | 45 | 1 | 0 | No | No |
| 17628138 | COMPOSITIONS FOR TREATMENT OF SUBSTANCE USE DISORDER | January 2022 | April 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17300930 | Azaquinazoline pan-KRas inhibitors | December 2021 | February 2025 | Allow | 38 | 2 | 1 | Yes | No |
| 17534789 | PREPARING METHOD OF LINEAR CARBONATE COMPOUNDS | November 2021 | December 2024 | Allow | 37 | 2 | 0 | No | No |
| 17598883 | CANNABINOID COMPOSITIONS AND USE THEREOF | September 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17436647 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | September 2021 | June 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17429722 | THIOSEMICARBAZONE COMPOUNDS AND USES THEREOF | August 2021 | October 2025 | Allow | 50 | 1 | 1 | Yes | No |
| 17429938 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | August 2021 | July 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17428353 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | August 2021 | May 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17427456 | TRANSIENT POTENTIAL MELASTATIN 8 (TRPM8) ANTAGONISTS AND RELATED METHODS | July 2021 | May 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17427311 | TOPICAL SANITIZING COMPOSITIONS | July 2021 | May 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17426442 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | July 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17426309 | INSECTICIDAL COMPOSITIONS RESISTANT TO ACTIVE INGREDIENT DEGRADATION AND PROCESS FOR PREPARATION THEREOF | July 2021 | February 2026 | Allow | 55 | 3 | 1 | No | No |
| 17425796 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | July 2021 | November 2024 | Allow | 39 | 0 | 0 | No | No |
| 17424699 | Cholinesterase inhibitor polymorph and application thereof | July 2021 | September 2024 | Allow | 38 | 0 | 0 | Yes | No |
| 17422700 | EGFR Inhibitors, Compositions and Methods Thereof | July 2021 | February 2025 | Abandon | 43 | 1 | 0 | Yes | No |
| 17422429 | USE OF CHLOROGENIC ACID IN PREPARING MEDICINE OR PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PAIN | July 2021 | July 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17422257 | SUBSTITUTED PYRROLIDINE AMIDES III | July 2021 | March 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17421474 | SYNERGIC PHARMACEUTICAL COMPOSITION OF ACECLOFENAC AND BETAMETHASONE FOR TREATING THE PAIN OF RHEUMATIC CONDITIONS OR POSTSURGICAL PAIN | July 2021 | December 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17421540 | MATERNAL DPA FOR BENEFIT OF MOTHER AND/OR CHILD'S MENTAL HEALTH | July 2021 | February 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17420421 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | July 2021 | February 2025 | Allow | 43 | 1 | 1 | No | No |
| 17420597 | METHODS AND MATERIALS FOR INCREASING TRANSCRIPTION FACTOR EB POLYPEPTIDE LEVELS | July 2021 | October 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17360699 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | June 2021 | April 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17416976 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | June 2021 | January 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17416997 | ORGANIC COMPOUNDS | June 2021 | September 2024 | Allow | 39 | 0 | 1 | Yes | No |
| 17416411 | KIF18A INHIBITORS | June 2021 | February 2025 | Allow | 44 | 1 | 1 | No | No |
| 17416415 | KIF18A INHIBITORS | June 2021 | March 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17413469 | HETEROCYCLIC COMPOUND | June 2021 | April 2024 | Allow | 34 | 0 | 0 | No | No |
| 17300000 | BENZIMIDAZOLE OR BENZOXAZOLE DERIVATIVES FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASE, DIABETES, AND COMPLICATIONS THEREOF | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17299325 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | June 2021 | December 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17299573 | KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17299270 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | June 2021 | May 2025 | Allow | 47 | 2 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner MCKOY, QUINCY ANDRE works in Art Unit 1626 and has examined 65 patent applications in our dataset. With an allowance rate of 64.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 43 months.
Examiner MCKOY, QUINCY ANDRE's allowance rate of 64.6% places them in the 25% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by MCKOY, QUINCY ANDRE receive 1.29 office actions before reaching final disposition. This places the examiner in the 18% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by MCKOY, QUINCY ANDRE is 43 months. This places the examiner in the 15% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +55.3% benefit to allowance rate for applications examined by MCKOY, QUINCY ANDRE. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 47.1% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 30.0% of cases where such amendments are filed. This entry rate is in the 43% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants file petitions regarding this examiner's actions, 60.0% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.8% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.